(Q28209496)

https://www.clinicaltrialsarena.com/news/china-covid-19-trials/

https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06?mod=home-page

chemical formula

C₂₇H₃₅N₆O₈P

0 references

canonical SMILES

Nc3ncnn2c3ccc2C(C#N)(C1O)OC(C1O)CO[P](=O)(NC(C)C(=O)OCC(CC)CC)Oc4ccccc4

0 references

isomeric SMILES

CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4

0 references

1 reference

https://www.biospace.com/article/data-from-gilead-s-compassionate-use-of-remdesivir-for-covid-19-looks-promising/

medical condition treated

COVID-19

statement disputed by

World Health Organization

1 reference

https://www.nbcnews.com/health/health-news/remdesivir-shouldn-t-be-used-hospitalized-covid-19-patients-who-n1248320

22 January 2022

The antiviral remdesivir should not be used as treatment for hospitalized Covid-19 patients, the World Health Organization said Thursday, only a month after the Food and Drug Administration approved the drug to treat patients over age 12 who are hospitalized with Covid-19. (English)

Ebola hemorrhagic fever

1 reference

https://www.drugsincontext.com/the-journey-of-remdesivir:-from-ebola-to-covid-19/

22 January 2022

intravenous infusion and defusion

Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. (English)

route of administration

0 references

legal status (medicine)

boxed warning

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

title

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

described at URL

https://pubmed.ncbi.nlm.nih.gov/34252308/

0 references

https://github.com/croningp/ChemputerAntiviralXDL/tree/master/Remdesivir

1 reference

https://twitter.com/Chemputation/status/1255645127281979397

has characteristic

ineffective drug

statement supported by

World Health Organization

point in time

20 November 2020

medical condition treated

COVID-19

2 references

https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients

22 January 2022

WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients. (English)

https://pubmed.ncbi.nlm.nih.gov/34252308/

22 January 2022

medical condition treated

However, the clinical efficacy of remdesivir for COVID-19 remains contentious, as several trials have not found statistically significant differences in either time to clinical improvement or mortality between remdesivir-treated and control groups. (English)

ineffective drug

Ebola hemorrhagic fever

1 reference

https://www.drugsincontext.com/the-journey-of-remdesivir:-from-ebola-to-covid-19/

22 January 2022